5 Oversold Stocks to Buy Right Now

3. Structure Therapeutics Inc. (NASDAQ:GPCR)

Number of Hedge Fund Holders: 58

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, showing up to 16.3% weight loss. With favorable FDA feedback, the company is on track to initiate a Phase 3 registrational trial in Q3 2026.

The company is also advancing its oral amylin receptor agonist pipeline, with lead candidate ACCG-2671 expected to enter multiple ascending dose studies in Q3 and a second candidate, ACCG-3535, beginning clinical trials in Q4. These programs aim to provide accessible oral small-molecule treatments for metabolic diseases.

Financially, Structure Therapeutics Inc. (NASDAQ:GPCR) holds $1.5 billion in cash, providing a runway through 2028 to support its clinical programs. Detailed updates on its aleniglipron and amylin portfolios are scheduled for presentation at the American Diabetes Association’s scientific sessions this June.

Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs.

1281292 - 11759070 - 1